Literature DB >> 23148373

The promise of combining inhibition of PI3K and PARP as cancer therapy.

Farah L Rehman1, Christopher J Lord, Alan Ashworth.   

Abstract

Analyses of in vitro and patient-derived in vivo models of breast cancer reveal that a combination of inhibitors of the enzymes PARP and phosphoinositide 3-kinase (PI3K) is a potentially effective treatment regimen for breast cancer tumors with elevated activity of the PI3K pathway. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23148373     DOI： 10.1158/2159-8290.CD-12-0433

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  14 in total

Review 1.  Molecules in medicine mini-review: isoforms of PI3K in biology and disease.

Authors:  Bart Vanhaesebroeck; Maria A Whitehead; Roberto Piñeiro
Journal:  J Mol Med (Berl)       Date:  2015-12-10       Impact factor: 4.599

Review 2.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

3.  Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Authors:  Panagiotis A Konstantinopoulos; William T Barry; Michael Birrer; Shannon N Westin; Karen A Cadoo; Geoffrey I Shapiro; Erica L Mayer; Roisin E O'Cearbhaill; Robert L Coleman; Bose Kochupurakkal; Christin Whalen; Jennifer Curtis; Sarah Farooq; Weixiu Luo; Julia Eismann; Mary K Buss; Carol Aghajanian; Gordon B Mills; Sangeetha Palakurthi; Paul Kirschmeier; Joyce Liu; Lewis C Cantley; Scott H Kaufmann; Elizabeth M Swisher; Alan D D'Andrea; Eric Winer; Gerburg M Wulf; Ursula A Matulonis
Journal:  Lancet Oncol       Date:  2019-03-14       Impact factor: 41.316

4.  Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.

Authors:  Albert A Antolín; Jordi Mestres
Journal:  Oncotarget       Date:  2014-05-30

Review 5.  The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.

Authors:  Melissa M Pham; Emily Hinchcliff; Monica Avila; Shannon N Westin
Journal:  Cancer J       Date:  2021 Nov-Dec 01       Impact factor: 2.074

Review 6.  PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?

Authors:  Michelle Lightfoot; Lauren Montemorano; Kristin Bixel
Journal:  Curr Oncol Rep       Date:  2020-02-17       Impact factor: 5.075

7.  The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.

Authors:  Hanjiao Qin; Linlin Liu; Shu Sun; Dan Zhang; Jiyao Sheng; Bingjin Li; Wei Yang
Journal:  PeerJ       Date:  2018-06-19       Impact factor: 2.984

8.  Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.

Authors:  Timothy A Yap; Rebecca Kristeleit; Vasiliki Michalarea; Stephen J Pettitt; Joline S J Lim; Suzanne Carreira; Desamparados Roda; Rowan Miller; Ruth Riisnaes; Susana Miranda; Ines Figueiredo; Daniel Nava Rodrigues; Sarah Ward; Ruth Matthews; Mona Parmar; Alison Turner; Nina Tunariu; Neha Chopra; Heidrun Gevensleben; Nicholas C Turner; Ruth Ruddle; Florence I Raynaud; Shaun Decordova; Karen E Swales; Laura Finneran; Emma Hall; Paul Rugman; Justin P O Lindemann; Andrew Foxley; Christopher J Lord; Udai Banerji; Ruth Plummer; Bristi Basu; Juanita S Lopez; Yvette Drew; Johann S de Bono
Journal:  Cancer Discov       Date:  2020-06-12       Impact factor: 38.272

9.  Novel insights into the neuroendocrine control of inflammation: the role of GR and PARP1.

Authors:  Fernando Aprile-Garcia; María Antunica-Noguerol; Maia Ludmila Budziñski; Ana C Liberman; Eduardo Arzt
Journal:  Endocr Connect       Date:  2013-12-19       Impact factor: 3.335

10.  Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.

Authors:  Li Chen; Liu Yang; Ling Yao; Xia-Ying Kuang; Wen-Jia Zuo; Shan Li; Feng Qiao; Yi-Rong Liu; Zhi-Gang Cao; Shu-Ling Zhou; Xiao-Yan Zhou; Wen-Tao Yang; Jin-Xiu Shi; Wei Huang; Xin Hu; Zhi-Ming Shao
Journal:  Nat Commun       Date:  2018-04-10       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.